Elucidating the causal associations and mechanisms between circulating immune cells and idiopathic pulmonary fibrosis: new insights from Mendelian randomization and transcriptomics by Han Yang, Xuanyu Wu, Xiang Xiao, Jiajing Chen, Xiaomin Yu, Wen Zhao, Fei Wang

Subjects: Get full text

Blood urea nitrogen-to-albumin ratio as a new prognostic indicator of 1-year all-cause mortality in patients with IPF by Shaobo Ge, Yuer Li, Rui Li, Jin Liu, Rui Zhang, Hongyan Fu, Jingjing Tang, Jie Zhang, Nali Zhang, Ming Zhang, Ming Zhang

Subjects: “…idiopathic pulmonary fibrosis…”
Get full text

Identifying health risk determinants and molecular targets in patients with idiopathic pulmonary fibrosis via combined differential and weighted gene co-expression analysis by Abu Tayab Moin, Md. Asad Ullah, Jannatul Ferdous Nipa, Mohammad Sheikh Farider Rahman, Afsana Emran, Md. Minhazul Islam, Swapnil Das, Tawsif Al Arian, Mohammad Mahfuz Enam Elahi, Mukta Akter, Umme Sadea Rahman, Arnab Halder, Shoaib Saikat, Mohammad Jakir Hosen

Subjects: “…idiopathic pulmonary fibrosis…”
Get full text

Commonly prescribed medications and risk of pneumonia and all-cause mortality in people with idiopathic pulmonary fibrosis: a UK population-based cohort study by Ann D. Morgan, Georgie M. Massen, Hannah R. Whittaker, Iain Stewart, Gisli Jenkins, Peter M. George, Jennifer K. Quint

Subjects: Get full text

METTL14-mediated m6A modification of DDIT4 promotes its mRNA stability in aging-related idiopathic pulmonary fibrosis by Dan Li, Li Qian, Yufeng Du, Lifang Liu, Ziyue Sun, Yongkang Han, Xiangrui Guo, Chao Shen, Zheng Zhang, Xuejun Liu

Subjects: “…Idiopathic pulmonary fibrosis…”
Get full text

The effectiveness and risks of Treating people with Idiopathic Pulmonary fibrosis with the Addition of Lansoprazole (TIPAL): study protocol for a randomised placebo-controlled multicentre clinical trial by Toby M Maher, A John Simpson, Anthony Cahn, David Thickett, Luke Vale, Allan B Clark, Nazia Chaudhuri, Ian Forrest, Lisa G Spencer, Christopher Ward, Stephen Jones, Ganesh Raghu, Andrew M Wilson, Helen Parfrey, Megan Jones, Matthew Hammond, Jaclyn Ann Smith, Shajahan Wahed

“…Introduction Idiopathic pulmonary fibrosis (IPF) is a chronic progressive fibrotic lung disease frequently complicated by gastro-oesophageal reflux disease. …”
Get full text

Beyond Tumors: The Pivotal Role of TRIM Proteins in Chronic Non-Tumor Lung Diseases by Huang X, Yu W, Wei A, Wang X, Chen S

Subjects: Get full text

Different Activity of the Biological Axis VEGF-Flt-1 (fms-Like Tyrosine Kinase 1) and CXC Chemokines between Pulmonary Sarcoidosis and Idiopathic Pulmonary Fibrosis: A Bronchoalveolar Lavage Study by Katerina M. Antoniou, Giannoula Soufla, Athanasia Proklou, George Margaritopoulos, Christiana Choulaki, Rena Lymbouridou, Katerina D. Samara, Demetrios A. Spandidos, Nikolaos M. Siafakas

“…We have previously shown a different local and systemic angiogenic profile of CXC chemokines in Idiopathic Pulmonary Fibrosis (IPF) patients compared to sarcoidosis. …”
Get full text

Carboplatin in combination with etoposide for advanced small cell lung cancer complicated with idiopathic interstitial pneumonia: a single-arm phase II study by Masaru Matsumoto, Yuji Minegishi, Katsuyuki Higa, Aya Fukuizumi, Naomi Onda, Susumu Takeuchi, Akihiko Miyanaga, Akihiko Gemma, Masahiro Seike

Subjects: Get full text

Comparison of Characteristics of Connective Tissue Disease-Associated Interstitial Lung Diseases, Undifferentiated Connective Tissue Disease-Associated Interstitial Lung Diseases, and Idiopathic Pulmonary Fibrosis in Chinese Han Population: A Retrospective Study by Lin Pan, Yuan Liu, Rongfei Sun, Mingyu Fan, Guixiu Shi

“…Our study compared the prevalence and characteristics of patients with connective tissue disease-associated interstitial lung disease (CTD-ILD), undifferentiated connective tissue disease-associated interstitial lung disease (UCTD-ILD), or idiopathic pulmonary fibrosis (IPF) between January 2009 and December 2012 in West China Hospital, western China. …”
Get full text

Treatment patterns and clinical profile in progressive pulmonary fibrosis: a Japanese cross-sectional survey by Hidekata Yasuoka, Yuko Waseda, Yuko Kaneko, Masateru Okazaki, Ryoko Iwasaki, Shoko Nagata, Mark Small, Haruyuki Ishii

Subjects: “…idiopathic pulmonary fibrosis…”
Get full text

HMGB1 Box A gene therapy to alleviate bleomycin-induced pulmonary fibrosis in rats by Rathasapa Patarat, Suchanart Chuaybudda, Sakawdaurn Yasom, Apiwat Mutirangura

Subjects: “…Idiopathic pulmonary fibrosis…”
Get full text

Predictive factors of fibrotic interstitial lung abnormality on high-resolution computed tomography scans: a prospective observational study by Kazuya Ichikado, Hidenori Ichiyasu, Kazuhiro Iyonaga, Kodai Kawamura, Yuko Yasuda, Keisuke Anan, Hiroko Okabayashi, Kimitaka Akaike, Noritaka Higashi, Takeshi Johkoh, Kiminori Fujimoto, Tetsuo Saito, Jun Morinaga, Minoru Yoshida, Katsuhiko Mitsuzaki, Takuro Sakagami

Subjects: Get full text

Reference values for the 1-minute sit-to-stand test to assess functional capacity and short-term mortality in people with idiopathic pulmonary fibrosis and fibrotic connective tissue related interstitial lung diseases: a prospective real-world cohort study by Meng-Yun Tsai, Kuo-Tung Huang, Chiann-Yi Hsu, Yi-Hsuan Yu, Pin-Kuei Fu

“…Results Of the 150 F-ILD patients, 37 (24.6%) had idiopathic pulmonary fibrosis (IPF), and 113 (75.4%) had connective tissue disease-related ILD (CTD-ILD). …”
Get full text

Postoperative Acute Exacerbation of IPF after Lung Resection for Primary Lung Cancer by Atsushi Watanabe, Nobuyoshi Kawaharada, Tetsuya Higami

“…Idiopathic pulmonary fibrosis (IPF) is characterized by slowly progressive respiratory dysfunction. …”
Get full text

Reduced tracheal stenosing effect of nintedanib in a patient with scarred posttraumatic tracheal stenosis and airflow limitation - a case report by Stefanie Klampfleitner, Andreas Fertl, Ositha Prinz, Martin Doerfler-Schalm, Dieter Munker, Markus O. Henke

“…Introduction: Nintedanib is a tyrosine kinase inhibitor and has been approved for the treatment of idiopathic pulmonary fibrosis (IPF) since 2020. In Clinical trials, the antifibrotic effect of nintedanib was shown. …”
Get full text

Steroids and/or Cytotoxic Agents Should Be Used Early in the Management of Patients with IPF -- The Pro Argument by Sat Sharma

“…However, the natural history and response to therapy differs substantially, as some categories have more favourable prognoses than others (2). Idiopathic pulmonary fibrosis (IPF) or fibrosing alveolitis is the clinical terminology for a specific interstitial pneumonia for which the pathological process is UIP. …”
Get full text

Updates in the management of connective tissue disease-associated interstitial lung disease by Chengappa Kavadichanda, G S R S N K Naidu

“…Most of the evidence in treating these cases is limited to a few trials in scleroderma and idiopathic pulmonary fibrosis along with several observational studies in other CTDs. …”
Get full text

Evaluation of Inflammatory Cytokine Secretion by Human Alveolar Macrophages by J. E. Losa García, F. M. Rodríguez, M. R. Martín de Cabo, M. J. García Salgado, J. P. Losada, L. G. Villarón, A. J. López, J. L. P. Arellano

“…Human AMs were collected by bronchoalveolar lavage (BAL) from four healthy controls and 13 patients with diffuse interstitial lung disease (five cases of sarcoidosis, three of hypersensitivity pneumonitis and five of idiopathic pulmonary fibrosis). AMs were cultured in the presence or absence of different concentrations of lipopolysaccharide (LPS), phorbolmyristate and gammainterferon. …”
Get full text

Phosphodiesterase-5 inhibitors: Raynaud's and beyond by Sanat Phatak, Sajal Ajmani, Vikas Agarwal, Durga Prasanna Misra

“…Recent evidences have suggested a potential antifibrotic role of these agents, and studies in idiopathic pulmonary fibrosis and systemic sclerosis-associated interstitial lung disease hold promise for future exploration of these agents for these indications.…”
Get full text